Ongoing and Future Research

CDG Therapeutics is currently expanding and developing its pipeline of novel, first-in-class peptides within one of the fastest growing markets in the pharmaceutical industry. The Company's proprietary compounds belong to the 'smart drug' or 'biologics' class, a potential $120 billion market.

CDG is developing and reporting on its pipeline of CPPs in the areas of metastatic, p53 positive solid tumors, neoangiogenesis, carriers for contrast and functional imaging agents, and inhibition of viral entry into host cells. One particular aspect we are exploring is the ability of these peptides to cross the blood brain barrier, opening up a research avenue in the treatment of primary CNS tumors. The pool of structures currently available to choose from, as well as a rich potential pipeline of peptide drug prototypes available inexpensively through chemical synthesis, provides a significant opportunity for development.

A Phase I human clinical trial of the lead compound, p28, was recently completed. In addition to exhibiting extraordinary safety attributes, the Phase I trial demonstrated significant regression in a variety of refractory solid tumors. These preliminary findings suggest that the CDG compounds may be effective in treating various types of cancer, if the data is confirmed through subsequent Phase II and Phase III clinical testing. Additionally, the significant adverse side effects associated with most existing cancer therapies appear to be absent in test subjects receiving p28.